Skip to main content
Fig. 1 | Genome Biology

Fig. 1

From: RNA editing in cancer impacts mRNA abundance in immune response pathways

Fig. 1

Overview of differential editing in cancer EMT. The following cancer types were studied: breast invasive carcinoma (BRCA), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), prostate adenocarcinoma (PRAD), ovarian serous cystadenocarcinoma (OV), kidney renal clear cell carcinoma (KIRC), head and neck squamous cell carcinoma (HNSC). a First two principal components of differential editing profiles separate tumor samples into epithelial (E) and mesenchymal (M) phenotypes across cancer types. b Distributions of differences in mean editing levels between E and M tumors in each cancer type. The number of differential editing sites is listed on top of each distribution. c Differential editing sites are mostly found in 3′ UTR and intronic regions in all cancer types, with higher proportions of 3′ UTR sites compared to that of all editing sites from the REDIportal database

Back to article page